| Name | Title | Contact Details |
|---|
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Offering the benefits of resort-style amenities and an independent lifestyle, with access to award-winning lifecare services providing added peace of mind.
RelayHealth Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Atlanta, GA. To find more information about RelayHealth Corporation, please visit www.relayhealth.com
NextGate`s mission is to address the fundamental challenge of data management in the healthcare industry: the uncertainties and missed opportunities caused by duplicate and disconnected records in a data population. While implementing interface engine technology for hospitals in the early 1990s, we noticed a troubling trend – as application systems became integrated and exchanged data with each other, problems caused by duplicate and incomplete patient records (previously confined to one system and its MPI) multiplied and contaminated the data quality of other systems. Because this technical issue could impact a patient`s health, we made it our goal to find a solution. The result was MatchMetrix®, a technology platform that invokes probabilistic and other algorithms to identify duplicate and potentially duplicate records within a single data set or across multiple data sets. All records are assigned a unique ID that serves as an enterprise-wide universal key for accurate identification and efficient data exchange. Duplicate records are merged, related records are linked together, and all of them are indexed into a trusted, consistent, and reliable registry accessible to any authorized application or user. We continue to develop solutions that help manage information that facilitates care team collaboration with accuracy and reliability.
Cohera Medical, Inc. is a rapidly growing medical device company actively developing surgical adhesives and sealants. TissuGlu Surgical Adhesive, the first synthetic adhesive approved for internal use, is an easily applied biocompatible, resorbable adhesive that requires no mixing or thawing. Indicated for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in abdominoplasty, TissuGlu Surgical Adhesive has been shown to eliminate the need for postoperative surgical drains in most abdominoplasty procedures.